Norma Quijada, MD
Endocrinology · Orchard Park, NYNPI 1134186877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 519 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,283 and has fallen 74.4% since, to $585 in 2025. Among endocrinology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 519 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$931
- Mannkind Corporation$729
- Lilly USA, LLC$691
- AbbVie$659
- AstraZeneca$540
- plus $3K from 23 others
What the payments were for
- Food & beverage$8,373100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 123 | $1,612 |
| Sanofi-aventis U.S. LLC | 51 | $931 |
| Mannkind Corporation | 39 | $729 |
| Lilly USA, LLC | 44 | $691 |
| AbbVie | 39 | $659 |
| AstraZeneca | 35 | $540 |
| Amneal Pharmaceuticals LLC | 21 | $457 |
| Insulet Corporation | 12 | $318 |
| Corcept Therapeutics | 18 | $276 |
| Boehringer Ingelheim | 15 | $269 |
| Johnson & Johnson | 26 | $257 |
| Exact Sciences | 12 | $213 |
| Merck | 12 | $188 |
| Dexcom, Inc. | 9 | $180 |
| Abbott | 11 | $159 |
| Amgen(2 entities) | 8 | $147 |
| Valeritas, Inc. | 8 | $120 |
| Shire North American Group Inc | 7 | $120 |
| Endo Pharmaceuticals Inc. | 8 | $114 |
| Ultragenyx Pharmaceutical Inc. | 4 | $74 |
| Bayer | 3 | $55 |
| IBSA Pharma Inc. | 2 | $47 |
| Amphastar Pharmaceuticals, Inc. | 3 | $46 |
| Pfizer | 2 | $44 |
| Medtronic | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Senseonics, Incorporated | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $24 |
How this compares
$8,395 in reported general payments places this provider in the 90th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 99 | $146,883 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $145,895 |
| JardianceEmpagliflozin | 85 | $91,196 |
| JanuviaSitagliptin Phosphate | 16 | $19,652 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,747 |
| FarxigaDapagliflozin Propanediol | 16 | $14,304 |
| Humalog Kwikpen U-100Insulin Lispro | 40 | $12,681 |
| SynthroidLevothyroxine Sodium | 118 | $12,089 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $6,082 |
| Levothyroxine Sodium | 311 | $5,759 |
| Icosapent Ethyl | 14 | $5,388 |
| Novolog FlexpenInsulin Aspart | 11 | $2,563 |
| Bromocriptine Mesylate | 11 | $2,076 |
| Calcitriol | 37 | $1,805 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 16 | $1,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,612 | $146,88399 claims |
| Boehringer IngelheimJardiance | $269 | $91,19685 claims |
| MerckJanuvia | $188 | $19,65216 claims |
| AstraZenecaFarxiga | $540 | $14,30416 claims |
| AbbVieSynthroid | $659 | $12,089118 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $457 | $7,384352 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 endocrinology providers in New York.
Other endocrinology in Orchard Park
- Philip RabitoNew York$712K
- Perry HersonWilliston Park$364K
- Olga LeonardiNew York$10K
- Isabela RomaoNew Hyde Park$10K
- Stephanie CharlesWest Nyack$10K
- Sanjay SahayGarden City$9K
- Swaminathan GiridharanBrooklyn$7K
- Julia KaplunSuffern$6K
- Elia KassabBrooklyn$1K
- Lauren GoldenNew York$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.